466 related articles for article (PubMed ID: 26873451)
21. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acromegaly.
Holdaway IM
Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
[TBL] [Abstract][Full Text] [Related]
23. [Current diagnosis and treatment of acromegaly].
Melgar V; Espinosa E; Cuenca D; Valle V; Mercado M
Rev Med Inst Mex Seguro Soc; 2015; 53(1):74-83. PubMed ID: 25680646
[TBL] [Abstract][Full Text] [Related]
24. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
25. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
Frohman LA; Bonert V
Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
[TBL] [Abstract][Full Text] [Related]
26. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
27. Acromegaly.
Chanson P; Salenave S
Orphanet J Rare Dis; 2008 Jun; 3():17. PubMed ID: 18578866
[TBL] [Abstract][Full Text] [Related]
28. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
29. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
31. Current treatment guidelines for acromegaly.
Melmed S; Jackson I; Kleinberg D; Klibanski A
J Clin Endocrinol Metab; 1998 Aug; 83(8):2646-52. PubMed ID: 9709926
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and treatment of acromegaly.
Katznelson L
Growth Horm IGF Res; 2005 Jul; 15 Suppl A():S31-5. PubMed ID: 16023876
[TBL] [Abstract][Full Text] [Related]
33. Acromegaly.
Chanson P; Salenave S; Kamenicky P
Handb Clin Neurol; 2014; 124():197-219. PubMed ID: 25248589
[TBL] [Abstract][Full Text] [Related]
34. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
35. 60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly.
Capatina C; Wass JA
J Endocrinol; 2015 Aug; 226(2):T141-60. PubMed ID: 26136383
[TBL] [Abstract][Full Text] [Related]
36. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY.
Shanik MH
Endocr Pract; 2016 Feb; 22(2):210-9. PubMed ID: 26437214
[TBL] [Abstract][Full Text] [Related]
37. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP).
Brue T; Rahabi H; Barry A; Barlier A; Bertherat J; Borson-Chazot F; Castinetti F; Cazabat L; Chabre O; Chevalier N; Christin-Maitre S; Cortet C; Drui D; Kamenicky P; Lançon C; Lioté F; Pellegrini I; Reynaud R; Salenave S; Tauveron I; Touraine P; Vantyghem MC; Vergès B; Vezzosi D; Villa C; Raverot G; Coutant R; Chanson P; Albarel F
Ann Endocrinol (Paris); 2023 Dec; 84(6):697-710. PubMed ID: 37579837
[TBL] [Abstract][Full Text] [Related]
38. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
39. Current pharmacotherapy for acromegaly: a review.
Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
[TBL] [Abstract][Full Text] [Related]
40. Current management of acromegaly.
Díez JJ; Iglesias P
Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
